Chlorogenic acid composition and method for its use in the treatment of Alzheimer's disease
The invention provides compositions comprising chlorogenic acid and methods for their use and manufacture in the treatment of Alzheimer's disease. The compositions can be formulated from botanical sources of chlorogenic acid including sunflower seed extract.
1. A method for treating Alzheimer's disease, comprising administering to a subject in need thereof a composition comprising sunflower seed extract obtained from aqueous extraction of sunflower seeds wherein said extract comprises a mixture of chlorogenic acids consisting of 4.1±1.42 w/w % 3-Caffeoylquinic acid (3-CQA), 28±4.65 w/w % 5-Caffeoylquinic acid (5-CQA), 6.5±2.25 w/w % 4-Caffeoylquinic acid (4-CQA), 0.84±0.26 w/w % 3,4-Dicaffeoylquinic acid (3,4-DiCQA), 1.23±0.34 w/w % 3,5-Dicaffeoylquinic acid (3,5-DiCQA), and 1.85±0.42 w/w % 4,5-Dicaffeoylquinic acid (4,5-DiCQA), and wherein administering said composition treats Alzheimer's disease in said subject.
2. The method of claim 1 , wherein said composition is administered to said subject at a dosage of about 200-400 mg per kilogram body weight.
3. The method of claim 1 , wherein said composition is administered to said subject orally.
4. The method of claim 1 , wherein said composition has a DPPH IC50 value of about 38.49 μg/mL in vitro.
5. The method of claim 1 , wherein said composition has an acetylcholinesterase IC50 value of about 43 μg/mL in vitro.
6. The method of claim 1 , wherein said composition is in a form selected from the group consisting of a powder, liquid, pill, tablet, pellet, capsule, thin film, solution, spray, syrup, linctus, lozenge, pastille, chewing gum, paste, vapor, suspension, emulsion, ointment, cream, lotion, liniment, gel, drop, topical patch, buccal patch, bead, gummy, gel, sol, and injectable solution.
7. The method of claim 1 , wherein administering said composition to said subject inhibits acetylcholinesterase activity in said subject.
8. The method of claim 1 , wherein administering said composition to said subject inhibits Tau phosphorylation in said subject.
9. The method of claim 1 , wherein administering said composition to said subject inhibits the formation of amyloid plaques in said subject.
10. The method of claim 1 , wherein administering said composition to said subject inhibits the formation of neurofibrillary tangles in said subject.
11. The method of claim 1 , wherein administering said composition to said subject inhibits the loss of GSH in said subject.
12. The method of claim 1 , wherein administering said composition to said subject increases GSH in said subject.
13. The method of claim 1 , wherein said composition comprises an excipient.